307.08
price up icon4.58%   13.44
pre-market  プレマーケット:  309.99   2.91   +0.95%
loading
前日終値:
$293.64
開ける:
$293.23
24時間の取引高:
481.45K
Relative Volume:
1.09
時価総額:
$6.70B
収益:
-
当期純損益:
$-518.67M
株価収益率:
-12.22
EPS:
-25.12
ネットキャッシュフロー:
$-438.32M
1週間 パフォーマンス:
+12.02%
1か月 パフォーマンス:
-0.44%
6か月 パフォーマンス:
+6.91%
1年 パフォーマンス:
+35.59%
1日の値動き範囲:
Value
$282.88
$308.46
1週間の範囲:
Value
$266.44
$308.46
52週間の値動き範囲:
Value
$168.25
$368.29

Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile

Name
名前
Madrigal Pharmaceuticals Inc
Name
セクター
Healthcare (1176)
Name
電話
404-380-9263
Name
住所
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Name
職員
376
Name
Twitter
@MadrigalPharma
Name
次回の収益日
2024-10-31
Name
最新のSEC提出書
Name
MDGL's Discussions on Twitter

MDGL を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
MDGL
Madrigal Pharmaceuticals Inc
307.08 6.70B 0 -518.67M -438.32M -25.12
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
427.89 110.19B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
687.80 75.58B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
647.39 38.71B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
264.99 34.18B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.25 28.11B 3.30B -501.07M 1.03B -2.1146

Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-06-28 開始されました Cantor Fitzgerald Neutral
2024-06-11 開始されました Wolfe Research Outperform
2024-04-22 開始されました BofA Securities Underperform
2024-03-15 アップグレード B. Riley Securities Sell → Neutral
2024-03-06 開始されました Citigroup Buy
2024-02-26 ダウングレード B. Riley Securities Neutral → Sell
2022-12-20 繰り返されました Oppenheimer Outperform
2022-12-19 繰り返されました H.C. Wainwright Buy
2022-12-19 繰り返されました Piper Sandler Overweight
2022-12-19 アップグレード Raymond James Underperform → Mkt Perform
2022-07-08 ダウングレード B. Riley Securities Buy → Neutral
2021-10-07 開始されました Jefferies Buy
2021-08-06 アップグレード BMO Capital Markets Market Perform → Outperform
2021-05-20 再開されました Goldman Buy
2020-11-24 再開されました Evercore ISI Outperform
2020-11-06 繰り返されました H.C. Wainwright Buy
2020-07-31 開始されました Piper Sandler Overweight
2020-06-05 開始されました BMO Capital Markets Market Perform
2020-05-05 開始されました Chardan Capital Markets Buy
2020-01-30 開始されました Canaccord Genuity Buy
2020-01-09 アップグレード UBS Neutral → Buy
2019-11-07 繰り返されました H.C. Wainwright Buy
2019-06-25 開始されました Stifel Hold
2019-06-10 アップグレード B. Riley FBR Neutral → Buy
2019-02-28 繰り返されました H.C. Wainwright Buy
2019-02-22 開始されました SVB Leerink Outperform
2019-01-23 開始されました UBS Neutral
2018-12-14 開始されました Wolfe Research Outperform
2018-12-12 開始されました B. Riley FBR Neutral
2018-11-19 ダウングレード Raymond James Mkt Perform → Underperform
2018-11-16 アップグレード Evercore ISI In-line → Outperform
2018-09-04 開始されました Citigroup Buy
2018-08-06 ダウングレード Goldman Buy → Neutral
2018-06-28 開始されました Raymond James Mkt Perform
すべてを表示

Madrigal Pharmaceuticals Inc (MDGL) 最新ニュース

pulisher
Jan 21, 2025

MDGL (Madrigal Pharmaceuticals) Dividends per Share : $0.00 (TTM As of Sep. 2024) - GuruFocus.com

Jan 21, 2025
pulisher
Jan 21, 2025

MDGL Stock Down 10% on Disappointing Preliminary Q4 Rezdiffra Sales - MSN

Jan 21, 2025
pulisher
Jan 20, 2025

MDGL (Madrigal Pharmaceuticals) Change In Working Capital : $7.82 Mil (TTM As of Sep. 2024) - GuruFocus.com

Jan 20, 2025
pulisher
Jan 19, 2025

Madrigal Pharmaceuticals gains amid takeover speculation - MSN

Jan 19, 2025
pulisher
Jan 19, 2025

MDGL (Madrigal Pharmaceuticals) Quick Ratio : 5.93 (As of Sep. 2024) - GuruFocus.com

Jan 19, 2025
pulisher
Jan 19, 2025

Madrigal Pharmaceuticals Rezdiffra Vies For Blockbuster Status In MASH - Seeking Alpha

Jan 19, 2025
pulisher
Jan 19, 2025

Have Insiders Sold Madrigal Pharmaceuticals Shares Recently? - Simply Wall St

Jan 19, 2025
pulisher
Jan 19, 2025

MDGL (Madrigal Pharmaceuticals) Net Income From Continuing Operations : $-518.67 Mil (TTM As of Sep. 2024) - GuruFocus.com

Jan 19, 2025
pulisher
Jan 19, 2025

MDGL (Madrigal Pharmaceuticals) EV-to-EBITDA : -10.99 (As of Jan. 19, 2025) - GuruFocus.com

Jan 19, 2025
pulisher
Jan 19, 2025

MDGL (Madrigal Pharmaceuticals) Capex-to-Operating-Cash-Flo - GuruFocus.com

Jan 19, 2025
pulisher
Jan 19, 2025

MDGL (Madrigal Pharmaceuticals) Earnings Yield % : N/A% (As of Jan. 19, 2025) - GuruFocus.com

Jan 19, 2025
pulisher
Jan 19, 2025

MDGL (Madrigal Pharmaceuticals) 3-Year Book Growth Rate : 9.60% (As of Sep. 2024) - GuruFocus.com

Jan 19, 2025
pulisher
Jan 19, 2025

MDGL (Madrigal Pharmaceuticals) Cash Flow for Lease Financing : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com

Jan 19, 2025
pulisher
Jan 19, 2025

MDGL (Madrigal Pharmaceuticals) Debt-to-Asset : 0.11 (As of Sep. 2024) - GuruFocus.com

Jan 19, 2025
pulisher
Jan 18, 2025

Madrigal Pharmaceuticals executive sells shares worth $120,847 - MSN

Jan 18, 2025
pulisher
Jan 18, 2025

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) VP Robert E. Waltermire Sells 442 Shares - MarketBeat

Jan 18, 2025
pulisher
Jan 18, 2025

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CMO Sells $461,789.49 in Stock - MarketBeat

Jan 18, 2025
pulisher
Jan 18, 2025

Madrigal Pharmaceuticals exec sells $461,789 in stock By Investing.com - Investing.com South Africa

Jan 18, 2025
pulisher
Jan 18, 2025

Madrigal Pharmaceuticals general counsel sells $75,734 in stock By Investing.com - Investing.com Australia

Jan 18, 2025
pulisher
Jan 18, 2025

Madrigal Pharmaceuticals general counsel sells $75,734 in stock - Investing.com India

Jan 18, 2025
pulisher
Jan 18, 2025

Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Up 7.4%Should You Buy? - MarketBeat

Jan 18, 2025
pulisher
Jan 18, 2025

Madrigal Pharmaceuticals exec sells $461,789 in stock - Investing.com India

Jan 18, 2025
pulisher
Jan 18, 2025

Shannon T. Kelley Sells 277 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock - MarketBeat

Jan 18, 2025
pulisher
Jan 18, 2025

Madrigal Pharmaceuticals executive sells shares worth $120,847 By Investing.com - Investing.com Canada

Jan 18, 2025
pulisher
Jan 17, 2025

Madrigral Pharmaceuticals gains amid takeover speculation - MSN

Jan 17, 2025
pulisher
Jan 17, 2025

Why Madrigal Pharmaceuticals Stock Was Plummeting This Week - MSN

Jan 17, 2025
pulisher
Jan 17, 2025

Madrigal Reports Robust 2024 Performance and Plans for Growth - MSN

Jan 17, 2025
pulisher
Jan 17, 2025

Why Madrigal Pharmaceuticals (MDGL) Stock is Moving Today - GuruFocus.com

Jan 17, 2025
pulisher
Jan 17, 2025

What is HC Wainwright's Forecast for MDGL FY2024 Earnings? - MarketBeat

Jan 17, 2025
pulisher
Jan 17, 2025

Hennion & Walsh Asset Management Inc. Reduces Stock Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat

Jan 17, 2025
pulisher
Jan 16, 2025

Trend Tracker for (MDGL) - Stock Traders Daily

Jan 16, 2025
pulisher
Jan 16, 2025

Madrigal CEO touts 'amazing' sales success of new MASH drug, but stock slumps - The Business Journals

Jan 16, 2025
pulisher
Jan 15, 2025

Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Down 14.4%Here's What Happened - MarketBeat

Jan 15, 2025
pulisher
Jan 14, 2025

Why Madrigal Pharmaceuticals Stock Is Sinking Today - MSN

Jan 14, 2025
pulisher
Jan 14, 2025

Madrigal Pharmaceuticals Enters Oversold Territory (MDGL) - Nasdaq

Jan 14, 2025
pulisher
Jan 14, 2025

HC Wainwright Issues Positive Forecast for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price - MarketBeat

Jan 14, 2025
pulisher
Jan 14, 2025

Madrigal Pharmaceuticals' SWOT analysis: Rezdiffra success drives stock outlook By Investing.com - Investing.com South Africa

Jan 14, 2025
pulisher
Jan 14, 2025

Madrigal Pharmaceuticals' SWOT analysis: Rezdiffra success drives stock outlook - Investing.com India

Jan 14, 2025
pulisher
Jan 13, 2025

MDGL Stock Dips Amid Preliminary 2024 Results Release - GuruFocus.com

Jan 13, 2025
pulisher
Jan 13, 2025

Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra - The Manila Times

Jan 13, 2025
pulisher
Jan 13, 2025

Madrigal's Rezdiffra Achieves $180M Sales in First Year as Groundbreaking MASH Treatment - StockTitan

Jan 13, 2025
pulisher
Jan 10, 2025

Madrigal Pharmaceuticals' SWOT analysis: stock poised for growth amid NASH market potential - Investing.com India

Jan 10, 2025
pulisher
Jan 10, 2025

Madrigal Pharmaceuticals’ SWOT analysis: stock poised for growth amid NASH market potential - Investing.com Nigeria

Jan 10, 2025
pulisher
Jan 10, 2025

Madrigal Pharmaceuticals' SWOT analysis: stock poised for growth amid NASH market potential By Investing.com - Investing.com South Africa

Jan 10, 2025
pulisher
Jan 10, 2025

Madrigal Pharmaceuticals' (MDGL) "Market Outperform" Rating Reaffirmed at JMP Securities - MarketBeat

Jan 10, 2025

Madrigal Pharmaceuticals Inc (MDGL) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$21.80
price up icon 4.81%
$73.47
price up icon 2.14%
$22.10
price up icon 16.13%
$367.97
price up icon 2.52%
biotechnology ONC
$218.70
price up icon 4.10%
$117.25
price up icon 4.75%
大文字化:     |  ボリューム (24 時間):